Saturday 17 October 2026
Export MYO’s income statement to Excel — free account
Myomo, Inc.
MYO Healthcare Medical Devices
Myomo, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $40.9 million, up 25.7% from fiscal 2024. In the quarter to June 2026, revenue grew 21.3%, EPS grew 18.2%, free cash flow grew 80.0% and total debt rose 199.5%, each against the same quarter a year earlier. Revenue growth for ten consecutive years; insiders bought in the last twelve months.
1.20
0.10
−7.69%
Follow MYO
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
1.03 | 0.70 | 0.93 | 0.90 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(22.84) | (13.08) | (33.40) | (20.52) | |
P/B ratio |
7.62 | 3.19 | 3.34 | 2.57 | |
Price to Tangible BV |
7.62 | 3.19 | 3.34 | 2.57 | |
EV/Sales |
0.99 | 0.62 | 0.79 | 0.70 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(6.04) | (1.82) | (2.24) | (2.90) | |
EV/FCF |
(4.72) | (1.49) | (1.82) | (2.09) | |
Quick Ratio |
1.73 | 2.19 | 2.69 | 1.94 | |
Current Ratio |
2.31 | 2.73 | 3.30 | 2.49 | |
Net Debt/EBITDA |
1.01 | 1.94 | 4.23 | 2.80 | |
Debt/Assets |
33.90% | 29.73% | 29.05% | 11.74% | |
Debt/Equity |
2.06 | 1.21 | 0.98 | 0.27 | |
Asset Turnover |
1.17 | 1.06 | 1.01 | 1.65 | |
Operating CF/Net income |
0.48 | 0.73 | 0.30 | 0.50 | |
Capex/Depreciation |
(0.10) | (0.71) | (0.33) | (2.27) | |
Interest Coverage |
— | (6.26) | — | — | |
Research and Development Expense of Revenue |
14.70% | 16.05% | 14.31% | 15.14% | |
Selling, General and Administrative Expense of Revenue |
76.69% | 83.41% | 78.68% | 83.56% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
8.91% | 5.91% | 4.98% | 5.79% | |
Graham Net Nets |
(0.11) | (0.07) | 0.01 | 0.09 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(32.69%) | (52.94%) | (40.66%) | (32.58%) | |
Free Cash Flow Yield |
(20.47%) | (59.80%) | (46.85%) | (36.89%) | |
Revenue per Share |
0.27 | 0.24 | 0.27 | 0.24 | |
Operating CF per Share |
(0.05) | (0.05) | (0.03) | (0.04) | |
Capex per Share |
0.00 | (0.01) | (0.01) | (0.02) | |
Free Cash Flow per Share |
(0.05) | (0.06) | (0.04) | (0.07) | |
Cash per Share |
0.32 | 0.37 | 0.44 | 0.30 | |
Shareholders Equity per Share |
0.14 | 0.21 | 0.27 | 0.35 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.14 | 0.21 | 0.27 | 0.35 | |
Free Cash Flow |
(2.02) | (2.69) | (1.49) | (2.88) | |
Working Capital |
13.92 | 16.27 | 19.21 | 13.75 | |
Capital Expenditures |
(0.08) | (0.49) | (0.35) | (1.05) | |
Net Current Asset Value |
(4.99) | (2.09) | 0.32 | 3.50 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.05 | 0.03 | 0.10 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
6.00 | 4.74 | 3.96 | 4.51 | |
Average Payables |
7.91 | 8.73 | 7.42 | 6.56 | |
Average Inventory |
3.65 | 3.46 | 3.14 | 3.51 | |
Average Assets |
37.01 | 38.81 | 40.44 | 25.20 | |
Average Common Equity |
11.72 | 15.34 | 18.06 | 11.96 |
Columns are period end dates